Interactions of IgG1 CH2 and CH3 Domains with FcRn

Antibody fragments are emerging as promising biopharmaceuticals because of their relatively small-size and other unique properties. However, when compared to full-size antibodies, most of the current antibody fragments of VH or VL display greatly reduced half-lives. A promising approach to overcome...

Descripción completa

Detalles Bibliográficos
Autores principales: Ying, Tianlei, Ju, Tina W., Wang, Yanping, Prabakaran, Ponraj, Dimitrov, Dimiter S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2014
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980117/
https://www.ncbi.nlm.nih.gov/pubmed/24765095
http://dx.doi.org/10.3389/fimmu.2014.00146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3980117/
https://www.ncbi.nlm.nih.gov/pubmed/24765095
http://dx.doi.org/10.3389/fimmu.2014.00146

Ejemplares similares